Portola Pharmaceuticals, Inc.
PTLA
PTLA was delisted on the 1st of July, 2020.
224 hedge funds and large institutions have $1.88B invested in Portola Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 87 increasing their positions, 67 reducing their positions, and 25 closing their positions.
64% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 25
30% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 67
6% more funds holding
Funds holding: 212 → 224 (+12)
11% less capital invested
Capital invested by funds: $2.12B → $1.88B (-$241M)
32% less call options, than puts
Call options by funds: $13.9M | Put options by funds: $20.3M
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$20.3M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.3M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$10.8M |
| 4 |
Morgan Stanley
New York
|
+$10.1M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$6.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
-$42.3M |
| 2 |
FAM
Fred Alger Management
New York
|
-$18.5M |
| 3 |
Goldman Sachs
New York
|
-$13.8M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
-$12.6M |
| 5 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$11.2M |
PTLA Hedge Fund Activity: Q4 2019 in Review
224 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2019, worth a combined $1.88B — down 11% from $2.12B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new PTLA positions and 25 closed out — a net gain of 16 holders — while 87 added to existing stakes and 67 trimmed.
The largest buyer was Pictet Asset Management (UK), adding an estimated $20.3M. The largest seller was Cadian Capital Management, cutting an estimated $42.3M.
- 224 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2019, up from 212 in Q3 2019.
- Funds reported $1.88B of Portola Pharmaceuticals, Inc. stock for Q4 2019, down 11% quarter-over-quarter.
- 41 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2019 and 25 closed out, a net change of +16 holders.
- The largest Portola Pharmaceuticals, Inc. buyer in Q4 2019 was Pictet Asset Management (UK), an estimated $20.3M added.
- The largest Portola Pharmaceuticals, Inc. seller in Q4 2019 was Cadian Capital Management, an estimated $42.3M sold.
Based on aggregated 13F filings for Q4 2019.